REIN THERAPEUTICS INC RNTX
ASignal's systematic analysis rates RNTX as Bearish.
Reflects the latest available analysis · analyzed Oct 31, 2026
The case on RNTX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $40.65M in total cash and zero debt
- Healthy liquidity ratios (current ratio: 4.27x, quick ratio: 4.19x)
- Price trading below 20-day and 50-day moving averages, potential for rebound
- RSI near neutral (40.94), not overbought or oversold
- Negative return on equity (-96.42%) and negative return on assets (-21.02%)
- Negative operating and free cash flow ($-18.83M and $-7.79M respectively)
- All margin metrics at 0.00%, indicating no profitability
- EV/EBITDA at -3.00x, signaling severe earnings distress
- No news coverage or Reddit mentions, suggesting low market interest or information scarcity
See the full verdict on RNTX
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RNTX
Most investors never get a second opinion, let alone several. ASignal runs RNTX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.